BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother. 2013;14:211-223. [PMID: 23331077 DOI: 10.1517/14656566.2013.763926] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Chang SS, Hu HY. Helicobacter pylori: Effect of coexisting diseases and update on treatment regimens. World J Gastrointest Pharmacol Ther 2015; 6(4): 127-136 [PMID: 26558147 DOI: 10.4292/wjgpt.v6.i4.127] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
2 Losurdo G, Cubisino R, Barone M, Principi M, Leandro G, Ierardi E, Di Leo A. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World J Gastroenterol 2018; 24(1): 139-149 [PMID: 29358890 DOI: 10.3748/wjg.v24.i1.139] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
3 Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther 2015; 6(4): 183-198 [PMID: 26558152 DOI: 10.4292/wjgpt.v6.i4.183] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
4 Pourmasoumi M, Najafgholizadeh A, Hadi A, Mansour-ghanaei F, Joukar F. The effect of synbiotics in improving Helicobacter pylori eradication: A systematic review and meta-analysis. Complementary Therapies in Medicine 2019;43:36-43. [DOI: 10.1016/j.ctim.2019.01.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
5 Wang Y, Zhao R, Wang B, Zhao Q, Li Z, Zhu-ge L, Yin W, Xie Y. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. Eur J Clin Pharmacol 2018;74:1-13. [DOI: 10.1007/s00228-017-2347-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
6 Özbalcı GS, Yürüker SS, Tarım İA, Çınar H, Polat AK, Özbalcı AB, Karabulut K, Erzurumlu K. First-line therapy in Helicobacter pylori eradication therapy: experience of a surgical clinic. Ulus Cerrahi Derg 2014;30:133-7. [PMID: 25931914 DOI: 10.5152/UCD.2014.2678] [Reference Citation Analysis]
7 Caliskan R, Tokman HB, Erzin Y, Saribas S, Yuksel P, Bolek BK, Sevuk EO, Demirci M, Yılmazli O, Akgul O, Kalayci F, Cakan H, Salih B, Bal K, Kocazeybek B. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop 2015;48:278-84. [PMID: 26108005 DOI: 10.1590/0037-8682-0027-2015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
8 Losurdo G, Leandro G, Principi M, Giorgio F, Montenegro L, Sorrentino C, Ierardi E, Di Leo A. Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: the meta-analysis may be influenced by ‘geographical weighting’. Int J Clin Pract. 2015;69:1112-1120. [PMID: 26138290 DOI: 10.1111/ijcp.12687] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
9 Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, Pisani A, Di Leo A. Noninvasive molecular analysis of Helicobacter pylori: Is it time for tailored first-line therapy? World J Gastroenterol 2017; 23(14): 2453-2458 [PMID: 28465629 DOI: 10.3748/wjg.v23.i14.2453] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
10 Talebi Bezmin Abadi A. Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int. 2014;2014:124607. [PMID: 24800203 DOI: 10.1155/2014/124607] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
11 Jin L, Li SY, Dai FL, Dai M, Xu WT. Efficacy and safety of Bifidobacterium combined with ilaprazole-containning quadruple therapy in rescue eradication of Helicobacter pyloriShijie Huaren Xiaohua Zazhi 2018; 26(4): 256-262 [DOI: 10.11569/wcjd.v26.i4.256] [Reference Citation Analysis]
12 Li BZ, Threapleton DE, Wang JY, Xu JM, Yuan JQ, Zhang C, Li P, Ye QL, Guo B, Mao C, Ye DQ. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052. [PMID: 26290044 DOI: 10.1136/bmj.h4052] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 11.6] [Reference Citation Analysis]
13 Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, Xie Y. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter. 2015;20:79-88. [PMID: 25381839 DOI: 10.1111/hel.12180] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
14 Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother 2021;22:729-41. [PMID: 33131337 DOI: 10.1080/14656566.2020.1845649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
15 Georgopoulos SD, Papastergiou V, Karatapanis S. Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era. Expert Opin Pharmacother. 2015;16:2307-2317. [PMID: 26330278 DOI: 10.1517/14656566.2015.1084503] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
16 Cammarota G, Ianiro G, Bibbò S, Di Rienzo TA, Masucci L, Sanguinetti M, Gasbarrini A. Culture-guided treatment approach for Helicobacter pylori infection: Review of the literature. World J Gastroenterol 2014; 20(18): 5205-5211 [PMID: 24833850 DOI: 10.3748/wjg.v20.i18.5205] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
17 Zhang H, Lam KH, Lam WWL, Wong SYY, Chan VSF, Au SWN. A putative spermidine synthase interacts with flagellar switch protein FliM and regulates motility in Helicobacter pylori: Structure-function studies of FliM-SpeE in H. pylori. Molecular Microbiology 2017;106:690-703. [DOI: 10.1111/mmi.13829] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
18 Xirouchakis E, Georgopoulos SD. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert Opin Pharmacother 2021;:1-10. [PMID: 34595999 DOI: 10.1080/14656566.2021.1982894] [Reference Citation Analysis]
19 Wang LM, Shang XJ. Therapeutic efficacy of pretreatment with compound Acidophilus lactob-acillus tablets followed by quadruple therapy in gastric ulcer patients with Helicobacter pylori infection. Shijie Huaren Xiaohua Zazhi 2018; 26(33): 1953-1958 [DOI: 10.11569/wcjd.v26.i33.1953] [Reference Citation Analysis]
20 Ohishi T, Masuda T, Abe H, Hayashi C, Adachi H, Ohba SI, Igarashi M, Watanabe T, Mimuro H, Amalia E, Inaoka DK, Mochizuki K, Kita K, Shibasaki M, Kawada M. Monotherapy with a novel intervenolin derivative, AS-1934, is an effective treatment for Helicobacter pylori infection. Helicobacter 2018;23:e12470. [PMID: 29488678 DOI: 10.1111/hel.12470] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
21 Frydman GH, Davis N, Beck PL, Fox JG. Helicobacter pylori Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of Biogeography. Helicobacter 2015;20:239-51. [PMID: 25728540 DOI: 10.1111/hel.12200] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
22 Smith JW, Mathis T, Benns MV, Franklin GA, Harbrecht BG, Larson G. Socioeconomic disparities in the operative management of peptic ulcer disease. Surgery 2013;154:672-8; discussion 678-9. [PMID: 23978592 DOI: 10.1016/j.surg.2013.06.036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
23 Georgopoulos SD, Papastergiou V, Martinez-Gonzalez B, Xirouchakis E, Familias I, Sgouras D, Mentis A, Karatapanis S. Hybrid therapy as first-line regimen for Helicobacter pylori eradication in a high clarithromycin resistance area: a prospective open-label trial. Ann Gastroenterol 2018;31:205-10. [PMID: 29507467 DOI: 10.20524/aog.2017.0221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
24 Pastrello C, Pasini E, Kotlyar M, Otasek D, Wong S, Sangrar W, Rahmati S, Jurisica I. Integration, visualization and analysis of human interactome. Biochemical and Biophysical Research Communications 2014;445:757-73. [DOI: 10.1016/j.bbrc.2014.01.151] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
25 Georgopoulos SD, Michopoulos S, Rokkas T, Apostolopoulos P, Giamarellos E, Kamberoglou D, Mentis A, Triantafyllou K. Hellenic consensus on Helicobacter pylori infection. Ann Gastroenterol 2020;33:105-24. [PMID: 32127732 DOI: 10.20524/aog.2020.0446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Zhang Y, Li H, Wang Q, Hao X, Li H, Sun H, Han L, Zhang Z, Zou Q, Sun X. Rationally Designed Self-Assembling Nanoparticles to Overcome Mucus and Epithelium Transport Barriers for Oral Vaccines against Helicobacter pylori. Adv Funct Mater 2018;28:1802675. [DOI: 10.1002/adfm.201802675] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
27 Zhang H, Au SWN. Helicobacter pylori does not use spermidine synthase to produce spermidine. Biochem Biophys Res Commun 2017;490:861-7. [PMID: 28648602 DOI: 10.1016/j.bbrc.2017.06.132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Yu HJ, Liu W, Chang Z, Shen H, He LJ, Wang SS, Liu L, Jiang YY, Xu GT, An MM, Zhang JD. Probiotic BIFICO cocktail ameliorates Helicobacter pylori induced gastritis. World J Gastroenterol 2015; 21(21): 6561-6571 [PMID: 26074694 DOI: 10.3748/wjg.v21.i21.6561] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
29 Stein M, Ruggiero P, Rappuoli R, Bagnoli F. Helicobacter pylori CagA: From Pathogenic Mechanisms to Its Use as an Anti-Cancer Vaccine. Front Immunol. 2013;4:328. [PMID: 24133496 DOI: 10.3389/fimmu.2013.00328] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
30 Liu P, Yue J, Han S, Deng T, Fu C, Zhu G, Chen D. A Cross-Sectional Survey of Dental Caries, Oral Hygiene, and Helicobacter pylori Infection in Adults. Asia Pac J Public Health 2013;25:49S-56S. [DOI: 10.1177/1010539513495555] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
31 Adebisi AO, Conway BR. Modification of drug delivery to improve antibiotic targeting to the stomach. Ther Deliv 2015;6:741-62. [PMID: 26149788 DOI: 10.4155/tde.15.35] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
32 Su J, Zhou X, Chen H, Hao B, Zhang W, Zhang G. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine (Baltimore) 2017;96:e5859. [PMID: 28207505 DOI: 10.1097/MD.0000000000005859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
33 Georgopoulos SD, Xirouchakis E, Martinez-Gonzales B, Zampeli E, Grivas E, Spiliadi C, Sotiropoulou M, Petraki K, Zografos K, Laoudi F. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. Eur J Intern Med. 2016;32:84-90. [PMID: 27134145 DOI: 10.1016/j.ejim.2016.04.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
34 Kanizaj TF, Kunac N. Helicobacter pylori: Future perspectives in therapy reflecting three decades of experience. World J Gastroenterol 2014; 20(3): 699-705 [PMID: 24574743 DOI: 10.3748/wjg.v20.i3.699] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
35 Abadi AT, Mobarez AM. First case of Helicobacter pylori infection resistant to seven antibiotics in Iran. Rev Soc Bras Med Trop 2014;47:666-7. [PMID: 25467273 DOI: 10.1590/0037-8682-0267-2013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Lopes D, Nunes C, Martins MC, Sarmento B, Reis S. Eradication of Helicobacter pylori: Past, present and future. J Control Release. 2014;189:169-186. [PMID: 24969353 DOI: 10.1016/j.jconrel.2014.06.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
37 Wang Y, Wang B, Lv ZF, Yang Y, Wang F, Wang H, Chen S, Xie Y, Zhou X. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter. 2014;19:372-381. [PMID: 24826809 DOI: 10.1111/hel.12136] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
38 Silva FM, Queiroz EC, Navarro-Rodriguez T, Barbuti RC, Mattar R, Iriya K, Lee JH, Eisig JN. Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers. Clinics (Sao Paulo) 2015;70:318-21. [PMID: 26039946 DOI: 10.6061/clinics/2015(05)02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Hu M, Wang Z. Treatment of Helicobacter pylori-associated gastritis using traditional Chinese medicine. Infection International 2018;7:1-5. [DOI: 10.2478/ii-2018-0009] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]